Opinion: How headlines about the RSV antibody injection could cloud parents’ decision-making
As theorists from Samuel Coleridge to Kenneth Burke have noted, language often does our thinking for us. In health care, all too often, that leads to problems.
In a particularly worrisome example of this, recent headlines about the new monoclonal antibody injection nirsevimab (trade named Beyfortus) designed to protect infants against the third culprit in last year’s tripledemic — respiratory syncytial virus (RSV) — contain language that may cloud parents’ decision-making about the new intervention.
